Wednesday, Aug 05, 2020 | Last Update : 04:09 AM IST

133rd Day Of Lockdown

Maharashtra45795629935616142 Tamil Nadu2682852087844349 Andhra Pradesh176333956251604 Karnataka145830692722704 Delhi1391561252264033 Uttar Pradesh100310572711817 West Bengal80984568841785 Telangana6894649675563 Gujarat65704485612529 Bihar6203140760349 Assam4816233429115 Rajasthan4667932832732 Haryana3779631226448 Odisha3768124483258 Madhya Pradesh3508225414912 Kerala279561629988 Jammu and Kashmir2239614856417 Punjab1901512491462 Jharkhand140705199129 Chhatisgarh10109761369 Uttarakhand8008484795 Goa7075511460 Tripura5520367528 Puducherry4147253758 Manipur301818147 Himachal Pradesh2879171013 Nagaland24056594 Arunachal Pradesh179011053 Chandigarh120671520 Meghalaya9173305 Sikkim7832971 Mizoram5022820
  Business   Companies  21 Jul 2020  FabiFlu more economical, effective treatment option for COVID-19: Glenmark tells DGCI

FabiFlu more economical, effective treatment option for COVID-19: Glenmark tells DGCI

REUTERS
Published : Jul 21, 2020, 3:38 pm IST
Updated : Jul 21, 2020, 3:52 pm IST

Glenmark also denied making any claims that “favipiravir alone” is effective in treatment of mild-to-moderate COVID-19 patients

 Glenmark Pharmaceuticals Ltd defended the pricing of its generic version of favipiravir, FabiFlu. (Representational Image)
  Glenmark Pharmaceuticals Ltd defended the pricing of its generic version of favipiravir, FabiFlu. (Representational Image)

BENGALURU: Glenmark Pharmaceuticals Ltd defended the pricing of its generic version of favipiravir, FabiFlu, on Tuesday, after India’s drug regulator had reportedly sent the company a notice on overpricing.

Shares of the Mumbai-based company fell as much as 5.8% on Monday after local media reports said the Drug Controller General of India (DCGI) pulled up Glenmark regarding the price of the tablet and other concerns.

 

"Compared to other therapies approved for emergency use in COVID-19, FabiFlu is much more economical and an effective treatment option," the company said in a statement.

Glenmark also denied making any claims that “favipiravir alone” is effective in treatment of mild-to-moderate COVID-19 patients.

FabiFlu’s price is significantly lower than versions of favipiravir in other countries, the company added. Its price of 75 rupees ($1.00) per tablet compares to 600 rupees per tablet in Russia, and between 200 rupees and 380 rupees per tablet in China, Bangladesh and Japan.

The concerns on overpricing and allegations regarding Glenmark’s claims of effectiveness of the drug in co-morbid conditions like hypertension and diabetes were raised by a member of India’s parliament, and were sent to the company by the DCGI in a letter dated July 17.

 

The statement pertaining to co-morbidity was not derived from Glenmark’s ongoing late-stage trial of favipiravir, the company said, adding that reference to co-morbidity was based on data from Japanese clinical studies and that none of the company’s product information for FabiFlu make any such claims.

Anti-flu drug favipiravir is manufactured under the brand name Avigan by a unit of Japan’s Fujifilm Holdings Corp. Japanese researchers have said a clinical trial of Avigan yielded inconclusive results as a treatment for COVID-19.

Tags: glenmark pharmaceuticals ltd, generic version, favipiravir, fabiflu, dcgi, overpricing
Location: India, Karnataka, Bengaluru